Eledon Pharmaceuticals to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026

Core Viewpoint - Eledon Pharmaceuticals is actively participating in the biotech sector, showcasing its leadership through a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026, highlighting its commitment to advancing immune-modulating therapies [1]. Company Overview - Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company focused on developing immune-modulating therapies for life-threatening conditions [3]. - The company's lead investigational product is tegoprubart, an anti-CD40L antibody that targets the CD40 Ligand, which has significant therapeutic potential [3]. - Eledon is conducting preclinical and clinical studies in various areas, including kidney allograft transplantation, xenotransplantation, islet cell transplantation, and amyotrophic lateral sclerosis (ALS) [3]. - The company is headquartered in Irvine, California, and more information can be found on its website [3].